Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that predominantly affects the pediatric population but also occurs in adults. The impact of atopic dermatitis on the daily life of patients in grossly underestimated. A study from the Charité Universität in Berlin published in the Journal of Allergy and Clinical Immunology amongst two thousand two patients and caregivers of children with moderate-to-severe atopic dermatitis showed that patients spend, on average, 1 of every 3 days in flare all year round. The majority of patients receive prescription topical corticosteroids to treat flares; however, 49% of respondents are concerned about using these agents. On average, patients and caregivers delay initiating treatment for 7 days after onset of a flare.
With todays’ treatment options, only 24% of patients and caregivers feel confident they can manage atopic dermatitis flares adequately. Seventy-five percent of caregivers and patients feel that being able to effectively control atopic dermatitis would be the single most important improvement to their or their child’s quality of life. The avoidable secondary economic cost of atopic dermatitis is estimated at €2 billion per year across the European Union.
Thus there is a clear unmet medical need. Madam Therapeutics is planning for a clinical trial in 2017 in atopic dermatitis patients with its lead product p-148. Details on the clinical study are anticipated soon.